To the Editor:Since development of R-CHOP for newly diagnosed diffuse large B-cell lymphoma (DLBCL) [1, 2], many attempts have been made to improve first-line therapy including studies which changed the timing/dosing of rituximab [3,4,5], substituted obinutuzumab for rituximab [6], added etoposide to CHOP in R-CHOEP [7], or changed to infusional regimens like dose-adjusted EPOCH-R [8].

致编辑：自R-CHOP用于新诊断的弥漫性大B细胞淋巴瘤（DLBCL）以来，已经进行了许多尝试来改善一线治疗，包括改变利妥昔单抗（3，4，5）的时间/剂量的研究，用奥比妥珠单抗替代利妥昔单抗（6），在R-CHOEP（7）中加入依托泊苷到CHOP中，或改为输注方案，如剂量调整的EPOCH-R（8）。

While many studies combined targeted drugs with R-CHOP [9,10,11], Pola-R-CHP was the first to significantly improve progression-free survival (PFS) in patients with DLBCL aged 18–80 with an International Prognostic Index (IPI) 2–5. While overall survival (OS) was not significantly different, the reduction in relapses led to adoption of Pola-R-CHP as the new standard in many countries [12].

虽然许多研究将靶向药物与R-CHOP[9,10,11]相结合，但Pola-R-CHP是第一个显着改善18-80岁DLBCL患者无进展生存期（PFS）的国际预后指数（IPI）2-5。虽然总生存率（OS）没有显着差异，但复发率的降低导致许多国家采用Pola-R-CHP作为新标准（12）。

However, gaps in knowledge remain, in particular for younger, high-risk patients with DLBCL where R-CHOEP is a common regimen in Germany and the Scandinavian countries [13,14,15]. This study compares Pola-R-CHP and R-CHOEP using individual patient data from respective phase 3 studies.MethodsStudy design, patient eligibility, randomization, endpoints, and statistical analyses of the two prospective, randomized phase 3 studies R-MegaCHOEP and POLARIX have been reported previously [7, 12].

然而，知识差距仍然存在，特别是对于年轻的高危DLBCL患者，其中R-CHOEP是德国和斯堪的纳维亚国家的常见方案[13，14，15]。这项研究使用来自各自3期研究的个体患者数据比较了Pola-R-CHP和R-CHOEP。方法先前已经报道了两项前瞻性随机3期研究R-MegaCHOEP和POLARIX的研究设计，患者资格，随机化，终点和统计分析[7，12]。

POLARIX was an international, double-blind, placebo-controlled study, whereas R-MegaCHOEP was an open label study performed in Germany. Full inclusion and exclusion criteria of both studies were published previously [7, 12].The current analysis compared outcomes of younger DLBCL patients (18–60 years) with age adjusted IPI (aaIPI) 2 or 3 treated with R-CHOEP on the R-MegaCHOEP study and patients treated with Pola-R-CHP on the POLARIX study.

POLARIX是一项国际双盲安慰剂对照研究，而R-MegaCHOEP是在德国进行的开放标签研究。这两项研究的完全纳入和排除标准先前已发表[7，12]。目前的分析比较了在R-MegaCHOEP研究中使用R-CHOEP治疗的年龄调整后IPI（aaIPI）2或3的年轻DLBCL患者（18-60岁）和在POLARIX研究中使用Pola-R-CHP治疗的患者的结果。

Protocol details are provided in Supplementary Data.The current analysis limited .

补充数据中提供了协议详细信息。目前的分析有限。

Data availability

数据可用性

Data availability statement: For eligible studies, qualified researchers may request access to individual patient-level clinical data through the clinical study data request platform. At the time of writing this request, the platform is Vivli (https://vivli.org/ourmember/roche/). For up-to-date details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://go.roche.com/data_sharing.

数据可用性声明：对于符合条件的研究，合格的研究人员可以通过临床研究数据请求平台请求访问个别患者级别的临床数据。在撰写此请求时，平台是Vivli(https://vivli.org/ourmember/roche/)。https://go.roche.com/data_sharing.

Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in risk of patient re-identification..

由于患者重新识别风险的潜在增加，罗氏外部多个数据源中个别患者的匿名记录不能也不应该链接。。

ReferencesCoiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.Article

参考文献Coiffer B，Lepage E，Briere J，Herbrecht R，Tilly H，Bouabdallah R等。CHOP化疗加利妥昔单抗与CHOP单独治疗老年弥漫性大B细胞淋巴瘤的比较。英格兰医学杂志2002；

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Cunningham D，Hawkes EA，Jack A，Qian W，Smith P，Mouncey P等。利妥昔单抗联合环磷酰胺，多柔比星，长春新碱和泼尼松龙治疗新诊断的弥漫性大B细胞非霍奇金淋巴瘤：14天与21天周期剂量强化的3期比较。

Lancet. 2013;381:1817–26.Article .

柳叶刀。2013年；381:1817-26。文章。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Pfreundschuh M, Poeschel V, Zeynalova S, Hanel M, Held G, Schmitz N, et al. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group. J Clin Oncol.

Pfreundschuh M，Poeschel V，Zeynalova S，Hanel M，Hold G，Schmitz N等。利妥昔单抗治疗弥漫性大B细胞淋巴瘤的优化（II）：在德国高级非霍奇金淋巴瘤研究小组的SMART-R-CHOP-14试验中延长利妥昔单抗暴露时间。J临床肿瘤学。

2014;32:4127–33.Article .

2014年；32:4127-33。文章。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, et al. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. Brit J Haematol. 2019;184:760–68.Article

Friedrichs B，Nickelsen M，Ziepert M，Altmann B，Haenel M，Viardot A等。将利妥昔单抗在侵袭性B细胞淋巴瘤高危患者中加倍-DENSE-R-MegaCHOEP试验的结果。英国J血液学。2019年；

CAS

中科院

Google Scholar

谷歌学者

Lugtenburg PJ, de Nully Brown P, van der Holt B, D’Amore FA, Koene HR, de Jongh E, et al. Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma: a randomized phase III trial of the HOVON and the nordic lymphoma group (HOVON-84). J Clin Oncol. 2020;38:3377–87.Article .

Lugtenburg PJ，de Nully Brown P，van der Holt B，D'Amore FA，Koene HR，de Jongh E等。利妥昔单抗CHOP联合利妥昔单抗早期强化治疗弥漫性大B细胞淋巴瘤：HOVON和北欧淋巴瘤组（HOVON-84）的随机III期临床试验。J临床肿瘤学。2020年；38:3377-87。文章。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Vitolo U, Trneny M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3529–37.Article

Vitolo U，Trneny M，Belada D，Burke JM，Carella AM，Chua N等。Obinutuzumab或利妥昔单抗加环磷酰胺，多柔比星，长春新碱和泼尼松治疗先前未治疗的弥漫性大B细胞淋巴瘤。J临床肿瘤学。2017年；35:3529–37.文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

Schmitz N，Nickelsen M，Ziepert M，Haenel M，Borchmann P，Schmidt C等。利妥昔单抗常规化疗（CHOEP-14）或利妥昔单抗高剂量化疗（MegaCHOEP）治疗年轻高危侵袭性B细胞淋巴瘤患者：一项开放标签，随机，3期临床试验（DSHNHL 2002-1）。

Lancet Oncol. 2012;12:1250–59.Article .

柳叶刀Oncol。2012年；12： 1250-59条。

Google Scholar

谷歌学者

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase iii intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37:1790–99.Article

Bartlett NL，Wilson WH，Jung SH，Hsi ED，Maurer MJ，Pederson LD等。剂量调整的EPOCH-R与R-CHOP相比作为弥漫性大B细胞淋巴瘤的一线治疗：iii期组间试验联盟/CALGB 50303的临床结果。J临床肿瘤学。2019年；37:1790–99.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285–95.Article

Younes A，Sehn LH，Johnson P，Zinzani PL，Hong X，Zhu J等。依鲁替尼和利妥昔单抗联合环磷酰胺，多柔比星，长春新碱和泼尼松治疗非生发中心B细胞弥漫性大B细胞淋巴瘤的随机III期临床试验。J临床肿瘤学。2019年；37:1285–95.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:649–62.Article

Davies A，Cummin TE，Barrans S，Maishman T，Mamot C，Novak U等。硼替佐米的基因表达谱添加到弥漫性大B细胞淋巴瘤（REMoDL-B）的标准化学免疫疗法中：一项开放标签，随机，3期试验。柳叶刀Oncol。2019年；20： 649-62.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39:1317–28.Article

Nowakowski GS，Chiappella A，Gascoyne RD，Scott DW，Zhang Q，Jurczak W等。稳健：来那度胺加R-CHOP与安慰剂加R-CHOP治疗先前未治疗的ABC型弥漫性大B细胞淋巴瘤患者的III期研究。J临床肿瘤学。2021年；39:1317–28.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351–63.Article

Tilly H、Morschhauser F、Sehn LH、Friedberg JW、TrněnýM、Sharman JP等人。Polatuzumab vedotin在先前未经治疗的弥漫性大B细胞淋巴瘤中的应用。《新英格兰医学杂志》2022年；386:351-63文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.

Frontzek F，Ziepert M，Nickelsen M，Altmann B，Glass B，Haenel M等。利妥昔单抗联合大剂量化疗（MegaCHOEP）或常规化疗（CHOEP-14）治疗年轻高危侵袭性B细胞淋巴瘤患者：一项随机，开放标签的3期试验的10年随访。

Lancet Haematol. 2021;8:e267–77.Article .

柳叶刀血液。2021年；8： e267-77。第条。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Holte H, Leppa S, Bjorkholm M, Fluge O, Jyrkkio S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.

Holte H，Leppa S，Bjorkholm M，Fluge O，Jyrkkio S，Delabie J等。针对年轻高危弥漫性大B细胞/滤泡性3级淋巴瘤患者进行剂量密集化化学免疫治疗，然后进行全身中枢神经系统预防：II期北欧淋巴瘤组研究的结果。

Ann Oncol. 2013;24:1385–92.Article .

安·昂科尔。2013年；。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Leppa S, Jorgensen J, Tierens A, Meriranta L, Ostlie I, de Nully Brown P, et al. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020;4:1906–15.Article

Leppa S，Jorgensen J，Tierens A，Meriranta L，Ostlie I，de Nully Brown P等。高危DLBCL患者受益于剂量密集型免疫化疗联合早期全身中枢神经系统预防。血液Adv.2020；4： 1906-15.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Download referencesAcknowledgementsThe POLARIX study (NCT03274492) was sponsored by F. Hoffmann-La Roche Ltd and Genentech, Inc. Third-party editorial assistance, under the direction of the authors, was provided by Rachel Bell, PhD, of Ashfield MedComms, an Inizio company, and was funded by F.

下载参考文献致谢POLARIX研究（NCT03274492）由F.Hoffmann La Roche Ltd和Genentech，Inc.赞助。在作者的指导下，第三方编辑协助由Inizio公司Ashfield MedComms的Rachel Bell博士提供，并由F。

Hoffmann-La Roche Ltd.FundingOpen Access funding enabled and organized by Projekt DEAL.Author informationAuthors and AffiliationsMedical Department A, University Hospital Münster, Münster, GermanyGeorg Lenz, Fabian Frontzek & Norbert SchmitzCentre Henri-Becquerel and University of Rouen, Rouen, FranceHervé TillyInstitute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, GermanyMarita Ziepert & Bettina AltmannUniversity of Montpellier, Montpellier, FranceCharles HerbauxOnkologie Lerchenfeld, Hamburg, GermanyMaike NickelsenGenentech Inc., South San Francisco, CA, USACalvin Lee, Jamie Hirata & Connie Lee BatleviF.

霍夫曼·拉罗氏有限公司（HoffmannLaRocheLtd.FundingOpen Access funding）由Projekt DEAL启用和组织。。

Hoffmann-La Roche Ltd, Basel, SwitzerlandDeniz SahinHoffmann-La Roche Ltd, Mississauga, ON, CanadaSaibah Chohan & Mark YanUniversity of Lille, Centre Hospitalier Universitaire, Lille, FranceFranck MorschhauserAuthorsGeorg LenzView author publicationsYou can also search for this author in.

霍夫曼·拉罗氏有限公司，巴塞尔，瑞士萨希霍夫曼·拉罗氏有限公司，密西沙加，安大略省，加拿大塞巴赫·乔汉和马克·扬恩大学，里尔大学中心医院，里尔，弗朗西夫兰克·莫尔施豪斯作者Georg LenzView作者出版物您也可以在中搜索这位作者。

PubMed Google ScholarHervé TillyView author publicationsYou can also search for this author in

PubMed Google ScholarHervéTillyView作者出版物您也可以在

PubMed Google ScholarMarita ZiepertView author publicationsYou can also search for this author in

PubMed Google ScholarMarita ZiepertView作者出版物您也可以在

PubMed Google ScholarBettina AltmannView author publicationsYou can also search for this author in

PubMed Google ScholarBettina AltmannView作者出版物您也可以在

PubMed Google ScholarCharles HerbauxView author publicationsYou can also search for this author in

PubMed Google ScholarCharles HerbauxView作者出版物您也可以在

PubMed Google ScholarFabian FrontzekView author publicationsYou can also search for this author in

PubMed Google ScholarFabian FrontzekView作者出版物您也可以在

PubMed Google ScholarMaike NickelsenView author publicationsYou can also search for this author in

PubMed谷歌学术型NickelsenView作者出版物您也可以在

PubMed Google ScholarCalvin LeeView author publicationsYou can also search for this author in

PubMed Google ScholarCalvin LeeView作者出版物您也可以在

PubMed Google ScholarJamie HirataView author publicationsYou can also search for this author in

PubMed谷歌学者Jamie HirataView作者出版物您也可以在

PubMed Google ScholarDeniz SahinView author publicationsYou can also search for this author in

PubMed Google ScholarDeniz SahinView作者出版物您也可以在

PubMed Google ScholarSaibah ChohanView author publicationsYou can also search for this author in

PubMed Google ScholarSaibah ChohanView作者出版物您也可以在

PubMed Google ScholarConnie Lee BatleviView author publicationsYou can also search for this author in

PubMed Google ScholarConnie Lee Batleview作者出版物您也可以在

PubMed Google ScholarMark YanView author publicationsYou can also search for this author in

PubMed Google ScholarMark YanView作者出版物您也可以在

PubMed Google ScholarFranck MorschhauserView author publicationsYou can also search for this author in

PubMed Google ScholarFranck MorschhauserView作者出版物您也可以在

PubMed Google ScholarNorbert SchmitzView author publicationsYou can also search for this author in

PubMed Google ScholarNorbert SchmitzView作者出版物您也可以在

PubMed Google ScholarContributionsGL, CL, JH and NS conceived the study design; MZ, BA, CL, JH, DS, SC, CLB and MY performed data analysis; MZ, BA, DS, SC, and MY curated the data; GL, CL, JH, DS, SC, CLB, MY and NS wrote the original draft of the manuscript; all authors reviewed and edited the subsequent manuscript drafts.Corresponding authorCorrespondence to.

PubMed Google ScholarContributionsGL，CL，JH和NS构思了研究设计；MZ，BA，CL，JH，DS，SC，CLB和MY进行了数据分析；MZ，BA，DS，SC和MY策划了数据；GL，CL，JH，DS，SC，CLB，MY和NS撰写了手稿的原稿；所有作者都审查并编辑了随后的手稿草稿。对应作者对应。

Georg Lenz.Ethics declarations

乔治·伦茨。道德宣言

Competing interests

相互竞争的利益

GL received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann-La Roche Ltd, and Verastem. GL received honoraria from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F.

GL从AGIOS，AQUINOX，AstraZeneca，Bayer，Celgene，Gilead，Janssen，MorphoSys，Novartis，F.Hoffmann-La Roche Ltd和Verastem获得了与本手稿无关的研究资助。GL获得了ADC Therapeutics，AbbVie，Amgen，AstraZeneca，Bayer，BeiGene，BMS，Celgene，Constellation，Enase，Genmab，Gilead，Hexal/Sandoz，Immagene，Incyte，Janssen，Karyopharm，Lilly，Miltenyi，MorphoSys，MSD，NanoString，Novartis，PentixaPharm，Pierre Fabre，F。

Hoffmann-La Roche Ltd, and Sobi..

Hoffman-La Roche有限公司和Sobi。。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Supplementary informationSupplemental dataRights and permissions

Additional informationPublisher的注释Springer Nature在已发布的地图和机构隶属关系中的管辖权主张方面保持中立。补充信息补充数据权限

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

开放获取本文是根据知识共享署名4.0国际许可证授权的，该许可证允许以任何媒体或格式使用，共享，改编，分发和复制，只要您对原始作者和来源给予适当的信任，提供知识共享许可证的链接，并指出是否进行了更改。

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

本文中的图像或其他第三方材料包含在文章的知识共享许可中，除非在材料的信用额度中另有说明。如果材料未包含在文章的知识共享许可中，并且您的预期用途不受法律法规的许可或超出许可用途，则您需要直接获得版权所有者的许可。

To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/..

要查看此许可证的副本，请访问http://creativecommons.org/licenses/by/4.0/..

Reprints and permissionsAbout this articleCite this articleLenz, G., Tilly, H., Ziepert, M. et al. Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials.

转载和许可本文引用本文Lenz，G.，Tilly，H.，Ziepert，M。等人Pola-R-CHP或R-CHOEP用于高危弥漫性大B细胞淋巴瘤年轻患者的一线治疗：两项随机3期试验的回顾性比较。

Leukemia (2024). https://doi.org/10.1038/s41375-024-02420-6Download citationReceived: 15 May 2024Revised: 18 September 2024Accepted: 19 September 2024Published: 25 September 2024DOI: https://doi.org/10.1038/s41375-024-02420-6Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

白血病（2024）。https://doi.org/10.1038/s41375-024-02420-6Download引文收到日期：2024年5月15日修订日期：2024年9月18日接受日期：2024年9月19日发布日期：2024年9月25日OI：https://doi.org/10.1038/s41375-024-02420-6Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供